A Double-blind Randomized, Placebo-controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers.

Trial Profile

A Double-blind Randomized, Placebo-controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs TAK 003 (Primary) ; TAK 003 (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Feb 2012 Status changed from active, no longer recruiting to completed, according to the Inviragen website.
    • 21 Feb 2012 Planned initiation date changed to 1 May 2010, according to ClinicalTrials.gov.
    • 21 Jul 2011 Planned end date changed from 1 Aug 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top